Access to biologics and JAK inhibitors for the treatment of rheumatic diseases in the biosimilars era in Poland: nation-level study
Description
CONCLUSIONS: In Poland, biosimilars-related savings contributed more so to improvement of higher priced innovative drugs availability, rather than less costly TNFis. Data-driven resource allocation and dedicated policy solutions facilitating access
